Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Xbrane Biopharma AB
Pharmaceutical Preparation ManufacturingSwedenSTO: XBRANE.ST
Last verified 1 year agoxbrane.com
Xbrane Biopharma AB, often simply referred to as Xbrane, is a pioneering pharmaceutical company headquartered in Sweden. Specialising in pharmaceutical preparation manufacturing, Xbrane is at the forefront of developing innovative biologics and biosimilars.
Founded in 2008, Xbrane has rapidly established itself as a key player in the biotechnology sector. Their core focus lies in the development and manufacturing of complex generic biologics, offering cost-effective and high-quality alternatives to established blockbuster drugs. This dedication positions Xbrane to significantly impact global healthcare accessibility.
Xbrane's unique approach combines advanced proprietary protein expression systems with comprehensive development capabilities. This allows them to produce difficult-to-make biologics, addressing unmet medical needs and offering substantial value to patients and healthcare systems worldwide.
36
DitchCarbon score
-6 vs industry average
Xbrane Biopharma AB’s score of 36 is lower than 48% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Xbrane Biopharma AB?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Xbrane Biopharma AB's reported carbon emissions
Xbrane Biopharma AB, a Swedish pharmaceutical preparation manufacturer, reported approximately 3,000 kg CO2e in Scope 2 emissions for 2025. This figure represents location-based Scope 2 emissions, with market-based Scope 2 emissions at approximately 2,000 kg CO2e for the same year. For 2023, the company reported about 8,000 kg CO2e in Scope 2 emissions, and for 2022, approximately 10,000 kg CO2e in Scope 2 emissions. Scope 1 emissions were reported as 0 kg CO2e for 2025 and 2022.
Xbrane Biopharma AB is committed to reducing its carbon footprint. The company aims to reduce its Scope 1 emissions to near zero by 2025 and its Scope 2 emissions to near zero by 2025. Additionally, Xbrane has a target to reduce its Scope 2 emissions by 50% from a 2020 baseline by 2030.
Assessing Xbrane Biopharma AB as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Xbrane Biopharma AB and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Xbrane Biopharma AB’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
On track94%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
At risk48%
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Behind target22%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Xbrane Biopharma AB1 year ago
36
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more